These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 20673554)

  • 41. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM; Yang R; Youakim JM
    Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.
    McIntyre RS; Cucchiaro J; Pikalov A; Kroger H; Loebel A
    J Clin Psychiatry; 2015 Apr; 76(4):398-405. PubMed ID: 25844756
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression.
    Toniolo RA; Silva M; Fernandes FBF; Amaral JAMS; Dias RDS; Lafer B
    J Neural Transm (Vienna); 2018 Feb; 125(2):247-257. PubMed ID: 29177955
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.
    Niufan G; Tohen M; Qiuqing A; Fude Y; Pope E; McElroy H; Ming L; Gaohua W; Xinbao Z; Huichun L; Liang S
    J Affect Disord; 2008 Jan; 105(1-3):101-8. PubMed ID: 17531327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.
    Berk M; Tiller JW; Zhao J; Yatham LN; Malhi GS; Weiller E
    J Clin Psychiatry; 2015 Jun; 76(6):728-34. PubMed ID: 25612216
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.
    Juruena MF; Ottoni GL; Machado-Vieira R; Carneiro RM; Weingarthner N; Marquardt AR; Fleig SS; Broilo L; Busnello EA
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):94-9. PubMed ID: 19007842
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
    Roth T; White D; Schmidt-Nowara W; Wesnes KA; Niebler G; Arora S; Black J
    Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.
    Katagiri H; Tohen M; McDonnell DP; Fujikoshi S; Case M; Kanba S; Takahashi M; Gomez JC
    BMC Psychiatry; 2013 May; 13():138. PubMed ID: 23672672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.
    Calabrese JR; Bowden CL; Sachs G; Yatham LN; Behnke K; Mehtonen OP; Montgomery P; Ascher J; Paska W; Earl N; DeVeaugh-Geiss J;
    J Clin Psychiatry; 2003 Sep; 64(9):1013-24. PubMed ID: 14628976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial.
    McIntyre RS; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Rosenblat JD; Brietzke E; Soczynska JK; Cosgrove VE; Miller S; Fischer EG; Kramer NE; Dunlap K; Suppes T; Mansur RB
    JAMA Psychiatry; 2019 Aug; 76(8):783-790. PubMed ID: 31066887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder.
    Kemp DE; Gao K; Fein EB; Chan PK; Conroy C; Obral S; Ganocy SJ; Calabrese JR
    Bipolar Disord; 2012 Nov; 14(7):780-9. PubMed ID: 23107222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study.
    Savitz A; Wajs E; Zhang Y; Xu H; Etropolski M; Thase ME; Drevets WC
    Int J Neuropsychopharmacol; 2021 Dec; 24(12):965-976. PubMed ID: 34324636
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
    Lee HB; Yoon BH; Kwon YJ; Woo YS; Lee JG; Kim MD; Bahk WM
    Clin Drug Investig; 2013 Oct; 33(10):743-53. PubMed ID: 23990283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Ketter TA; Cucchiaro J; Loebel A
    J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
    Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
    J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group.
    Pande AC; Crockatt JG; Janney CA; Werth JL; Tsaroucha G
    Bipolar Disord; 2000 Sep; 2(3 Pt 2):249-55. PubMed ID: 11249802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.